Skip to main content
NCBI home page
CNS Drug Reviews logoLink to CNS Drug Reviews
. 2006 Jun 7;11(3):229–252. doi: 10.1111/j.1527-3458.2005.tb00045.x

Cotinine, a Neuroactive Metabolite of Nicotine: Potential for Treating Disorders of Impaired Cognition

Alvin V Terry Jr 1,2,3, Caterina M Hernandez 1, Elizabeth J Hohnadel 1, Kristy P Bouchard 2, Jerry J Buccafusco 3,4,✉
PMCID: PMC6741756  PMID: 16389292

ABSTRACT

The pharmacological effects of the tobacco‐derived alkaloid nicotine have been widely studied in humans and animals for decades. However, relatively little attention has been given to the potential actions of its major metabolite, cotinine. After nicotine consumption the duration of cotinine's presence in blood and brain greatly exceeds that of nicotine. Therefore, cotinine could mediate the more protracted pharmacological effects of nicotine. The studies described in this report were thus designed to further investigate certain neuropharmacological actions of cotinine. Behavioral tests (e.g., delayed matching‐to‐sample) were conducted in aged rhesus monkeys to assess the effects of cotinine on working memory and attention. In rats a prepulse inhibition (PPI) procedure was used to assess the effects of the compound on auditory gating — a method for predicting the potential antipsychotic properties of drugs. Cotinine exhibited significant effectiveness in these tasks. The drug was also cytoprotective in differentiated PC‐12 cells with a potency equivalent to that of nicotine. The effects of chronic cotinine treatment on the expression of nicotinic and muscarinic acetylcholine receptors in rat brain were measured by [125I]epibatidine, [125I]α‐bungarotoxin ([125I]BTX), [3H]pirenzepine ([3H]PRZ), and [3H]AFDX‐384 ([3H]AFX) autoradiography. Unlike nicotine, cotinine failed to upregulate the expression of brain nicotinic receptors. Based on its relative safety in man, cotinine should prove useful in the treatment of diseases of impaired cognition and behavior without exhibiting the toxicity usually attributed to nicotine.

Keywords: Keywords: Attention, Cognition, Cotinine, Cytoprotection, Delayed response task, Memory, Nicotine, Nicotinic receptors, Non‐human primates, Prepulse inhibition

Full Text

The Full Text of this article is available as a PDF (229.6 KB).

References

  • 1. Adler LE, Olincy A, Waldo M, et al. Schizophrenia, sensory gating, and nicotinic receptors. Schizophr Bull 1998;24:189–202. [DOI] [PubMed] [Google Scholar]
  • 2. Audesirk T, Cabell L. Nanomolar concentrations of nicotine and cotinine alter the development of cultured hippocampal neurons via non‐acetylcholine receptor‐mediated mechanisms. Neurotoxicology 1999;20:639–646. [PubMed] [Google Scholar]
  • 3. Barbacid M. The Trk family of neurotrophin receptors. J Neurobiol 1994;25:1386–1403. [DOI] [PubMed] [Google Scholar]
  • 4. Barrantes FJ. The acetylcholine receptor ligand‐gated channel as a molecular target of disease and therapeutic agents. Neurochem Res 1997;22:391–400. [DOI] [PubMed] [Google Scholar]
  • 5. Blumenthal EM, Conroy WG, Romano SJ, Kassner PD, Berg DK. Detection of functional nicotinic receptors blocked by α‐bungarotoxin on PC‐12 cells and dependence of their expression on post‐translational events. J Neurosci 1997;17:6094–6104. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6. Braff DL, Grillion C, Geyer MA. Gating and habituation of the startle reflex in schizophrenic patients. Arch Gen Psychiat 1992;49:206–215. [DOI] [PubMed] [Google Scholar]
  • 7. Briggs CA, McKenna DG. Activation and inhibition of the human α7 nicotinic acetylcholine receptor by agonists. Neuropharmacology 1998;37:1095–1102. [DOI] [PubMed] [Google Scholar]
  • 8. Briggs CA, McKenna DG, Monteggia LM, et al. Gain of function mutation of the α7 nicotinic receptor: Distinct pharmacology of the α7V242T variant. Eur J Pharmacol 1999;366:301–308. [DOI] [PubMed] [Google Scholar]
  • 9. Buccafusco JJ, Prendergast M, Terry AV Jr, Jackson WJ. Cognitive effects of nicotinic cholinergic agonists in non‐human primates. Drug Devel Res 1996;38:196–203. [Google Scholar]
  • 10. Buccafusco JJ, Terry AV, Jr. The potential role of cotinine in the cognitive and neuroprotective actions of nicotine. Life Sci 2003;72:2931–2942. [DOI] [PubMed] [Google Scholar]
  • 11. Buccafusco JJ, Bencherif M, Lippillo PM, Letchworth SR. Drug‐induced cognitive improvement: Evidence for pharmacokinetic‐pharmacodynamic discordance. Trends Pharmacol Sci 2005;26:352–360. [DOI] [PubMed] [Google Scholar]
  • 12. Carlson NG, Bacchi A, Rogers SW, Gahring LC. Nicotine blocks TNF‐α‐mediated neuroprotection to NMDAby an alpha‐bungarotoxin‐sensitive pathway. J Neurobiol 1998;35:29–36. [DOI] [PubMed] [Google Scholar]
  • 13. Chao MV. Neurotrophin receptors: A window into neuronal differentiation. Neuron 1992;9:583–593. [DOI] [PubMed] [Google Scholar]
  • 14. Clarke PBS, Schwartz RD, Paul SM, Pert CB, Pert A. Nicotinic binding in rat brain: Autoradiographic comparison of [3H]acetylcholine, [3H]nicotine, and [125I]alpha‐bungarotoxin. J Neurosci 1985;5:1307–1315. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15. Corringer PJ, Le Novere N, Changeux JP. Nicotinic receptors at the amino acid level. Ann Rev Pharmacol Toxicol 2000;40:431–458. [DOI] [PubMed] [Google Scholar]
  • 16. Crooks PA, Dwoskin LP. Contribution of CNS nicotine metabolites to the neuropharmacological effects of nicotine and tobacco smoking. Biochem Pharmacol 1997;54:743–753. [DOI] [PubMed] [Google Scholar]
  • 17. Dajas‐Bailador FA, Lima PA, Wonnacott S. The α7‐nicotinic acetylcholine receptor subtype mediates nicotine protection against NMDA excitotoxicity in primary hippocampal cultures through a Ca2+ dependent mechanism. Neuropharmacology 2000;39:2799–2807. [DOI] [PubMed] [Google Scholar]
  • 18. Dani JA. Overview of nicotinic receptors and their roles in the central nervous system. Biol Psychiatry 2001;49:166–174. [DOI] [PubMed] [Google Scholar]
  • 19. Donnelly‐Roberts DL, Xue IC, Arneric SP, Sullivan JP. In vitro neuroprotective properties of the novel cholinergic channel activator (ChCA), ABT‐418. Brain Res 1996;719:36–44. [DOI] [PubMed] [Google Scholar]
  • 20. Drisdel RC, Green WN. Neuronal α‐bungarotoxin receptors are α7 subunit homomers. J Neurosci 2000;20:133–139. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21. Gattu M, Pauly JR, Boss KL, Summers JB, Buccafusco JJ. Cognitive impairment in spontaneously hypertensive rats: Role of central nicotinic receptors. Part I. Brain Res 1997;771:89–103. [DOI] [PubMed] [Google Scholar]
  • 22. Gattu M, Terry AV, Pauly JR, Buccafusco JJ. Cognitive impairment in spontaneoously hypertensive rats: Role of central nicotinic receptors. Part II. Brain Res 1997;771:104–114. [DOI] [PubMed] [Google Scholar]
  • 23. Geyer MA, Krebs‐Thomson K, Braff DL, Swerdlow NR. Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: A decade in review. Psychopharmacology (Berlin) 2001;156:117–154. [DOI] [PubMed] [Google Scholar]
  • 24. Grady SR, Grun EU, Marks MJ, Collins AC. Pharmacological comparison of transient and persistent [3H]dopamine release from mouse striatal synaptosomes and response to chronic L‐nicotine treatment. J Pharmacol Exp Ther 1997;282:232–243. [PubMed] [Google Scholar]
  • 25. Graham FK. The more or less startling effects of weak prestimulation. Psychophysiology 1975;12:238–248. [DOI] [PubMed] [Google Scholar]
  • 26. Hatsukami DK, Grillo M, Pentel PR, Oncken C, Bliss R. Safety of cotinine in humans: Physiologic, subjective, and cognitive effects. Pharmacol Biochem Behav 1997;57:643–650. [DOI] [PubMed] [Google Scholar]
  • 27. Henderson LP, Gdovin MJ, Liu C, Gardner PD, Maue RA. Nerve growth factor increases nicotinic ACh receptor gene expression and current density in wild‐type and protein kinase A‐deficient PC‐12 cells. J Neurosci 1994;14:1153–1163. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28. Hernandez CM, Terry AV, Jr. Repeated nicotine exposure in rats: effects on memory function, cholinergic markers and nerve growth factor. Neuroscience 2005;130:997–1012. [DOI] [PubMed] [Google Scholar]
  • 29. Herzig KE, Callaway E, Halliday R, Naylor H, Benowitz N. Effects of cotinine on information processing in nonsmokers. Psychopharmacology 1998;135:127–32. [DOI] [PubMed] [Google Scholar]
  • 30. Jones CK, Eberle EL, Shaw DB, McKinzie DL, Shannon HE. Pharmacologic interactions between the muscarinic cholinergic and dopaminergic systems in the modulation of prepulse inhibition in rats. J Pharmacol Exp Ther 2005;312:1055–1063. [DOI] [PubMed] [Google Scholar]
  • 31. Jonnala RR, Buccafusco JJ. Relationship between cell surface α7 nicotinic receptor expression and neuroprotection induced by several nicotinic receptor agonists. J Neurosci Res 2001;66:565–572. [DOI] [PubMed] [Google Scholar]
  • 32. Jonnala RR, Graham JH III, Terry AV Jr, Beach JW, Young JA, Buccafusco JJ. Relative levels of cytoprotection produced by analogs of choline and the role of α7‐nicotinic acetylcholine receptors. Synapse 2003;47:262–269. [DOI] [PubMed] [Google Scholar]
  • 33. Kaneko S, Maeda T, Kume T, et al. Nicotine protects cultured cortical neurons against glutamate‐induced cytotoxicity via α7‐neuronal receptors and neuronal CNS receptors. Brain Res 1997;765:135–140. [DOI] [PubMed] [Google Scholar]
  • 34. Kihara T, Shimohama S, Urushitani M, et al. Stimulation of α4β2 nicotinic acetylcholine receptors inhibits β‐amyloid toxicity. Brain Res 1998;792:331–334. [DOI] [PubMed] [Google Scholar]
  • 35. Lindstrom J. Nicotinic acetylcholine receptors in health and disease. Mol Neurobiol 1997;15:193–222. [DOI] [PubMed] [Google Scholar]
  • 36. Linville DG, Williams S, Raszkiewicz JL, Arneric SP. Nicotinic agonists modulate basal forebrain control of cortical cerebral blood flow in anesthetized rats. J Pharmacol Exp Ther 1993;267:440–448. [PubMed] [Google Scholar]
  • 37. Paterson D, Nordberg A. Neuronal nicotinic receptors in the human brain. Prog Neurobiol 2000;61:75–111. [DOI] [PubMed] [Google Scholar]
  • 38. Paxinos G, Watson C. The Rat Brain in Stereotaxic Coordinates. San Diego : Academic Press, 1998. [Google Scholar]
  • 39. Perry DC, Xiao Y, Nguyen HN, et al. Measuring nicotinic receptors with characteristics of α4β2, α3β2 and α3β4 subtypes in rat tissues by autoradiography. J Neurochem 2002;82:468–481. [DOI] [PubMed] [Google Scholar]
  • 40. Radek RJ. Effects of nicotine on cortical high voltage spindles in rats. Brain Res 1993;625:23–28. [DOI] [PubMed] [Google Scholar]
  • 41. Rangwala F, Drisdel RC, Rakhilin S, et al Neuronal α‐bungarotoxin receptors differ structurally from other nicotinic acetylcholine receptors. J Neurosci 1997;17:8201–8212. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42. Rezvani AH, Levin ED. Cognitive effects of nicotine. Biol Psychiatry 2001;49:258–267. [DOI] [PubMed] [Google Scholar]
  • 43. Risner ME, Goldberg SR, Prada JA, Cone EJ. Effects of nicotine, cocaine and some of their metabolites on schedule‐controlled responding by beagle dogs and squirrel monkeys. J Pharmacol Exp Ther 1985;234:113–119. [PubMed] [Google Scholar]
  • 44. Rowell PP. Nanomolar concentrations of nicotine increase the release of [3H]dopamine form rat striatal synaptosomes. Neurosci Letts 1995;189:171–175. [DOI] [PubMed] [Google Scholar]
  • 45. Rowell P. Effects of nicotine on dopaminergic neurotransmission In: Levin ED, Ed. Nicotine and the nervous system. New York : CRC Press, 2002;51–80. [Google Scholar]
  • 46. Shimohama S, Kihara T. Nicotinic receptor‐mediated protection against beta‐amyloid neurotoxicity. Biol Psychiatry 2001;49:233–239. [DOI] [PubMed] [Google Scholar]
  • 47. Snider WD. Functions of the neurotrophins during nervous system development: What the knockouts are teaching us. Cell 1994;77:627–638. [DOI] [PubMed] [Google Scholar]
  • 48. Stanhope KJ, Mirza NR, Bickerdike MJ, et al. The muscarinic receptor agonist xanomeline has an antipsychotic‐like profile in the rat. J Pharmacol Exp Ther 2001;299:782–792. [PubMed] [Google Scholar]
  • 49. U. S. Department of Health and Human Services : The health consequences of smoking: Nicotine addiction. Areport of the Surgeon General. Washington , D.C. : U.S. Government Printing Office, 1988. [Google Scholar]
  • 50. Vainio PJ, Tornquist K, Tuominen RK. Cotinine and nicotine inhibit each other's calcium responses in bovine chromaffin cells. Toxicol Appl Pharmacol 2000;163:183–187. [DOI] [PubMed] [Google Scholar]
  • 51. Vainio PJ, Tuominen RK. Cotinine binding to nicotinic acetylcholine receptors in bovine chromafin cell and rat brain membranes. Nicotine Tobacco Res 2001;3:177–182. [DOI] [PubMed] [Google Scholar]
  • 52. van der Zee EA, Luiten PG. Muscarinic acetylcholine receptors in the hippocampus, neocortex and amygdala: A review of immunocytochemical localization in relation to learning and memory. Prog Neurobiol 1999;58:409–471. [DOI] [PubMed] [Google Scholar]
  • 53. Yong T, Zheng MQ, Linthicum DS. Nicotine induces leukocyte rolling and adhesion in the cerebral microcirculation of the mouse. J Neuroimmunol 1997;80:158–164. [DOI] [PubMed] [Google Scholar]

Articles from CNS Drug Reviews are provided here courtesy of Wiley

RESOURCES